Expression of Fas (CD95/APO-1) ligand by human breast cancers: Significance for tumor immune privilege

Clinical and Diagnostic Laboratory Immunology

Volumn 6, Issue 4, 1999, Pages 457-463

  O'Connell, Joe ^a   Bennett, Michael W ^a   O'Sullivan, Gerald C ^b   O'Callaghan, Jim ^a   Collins, J Kevin ^a   Shanahan, Fergus ^a  

^a National University of Ireland ^*  (Ireland)

^b MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MESSENGER RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

EID: 0032808568     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.6.4.457-463.1999     Document Type: Article

References (39)

1. Alderson, M. R., T. W. Tough, T. Davis-Smith, S. Braddy, B. Falk, K. A. Schooley, R. G. Goodwin, C. A. Smith, F. Ramsdell, and D. H. Lynch. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181:71-77.
2. Allison, J., H. M. Georgiou, A. Strasser, and D. L. Vaux. 1997. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration hut does not confer immune privilege upon islet allograft. Proc. Natl. Acad. Sci. USA 94:3943-3947.
3. Arai, H., D. Gordon, E. G. Nabel, and G. J. Nabel. 1997. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA 94: 13862-13867.
4. Arai, H., S. Y. Chan, D. K. Bishop, and G. J. Nabel. 1997. Inhibition of the alloantibody response by CD95 ligand. Nat. Med. 3:843-848.
5. Bargou, R. C., C. Wagener, K. Bommert, M. Y. Mapara, P. T. Daniel, W. Arnold, M. Dietel, H. Guski, A. Feller, H. D. Royer, and B. Dorken. 1996. Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J. Clin. Invest. 97:2651-2659.
6. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R. C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature 377:630-632.
7. Bennett, M. W., J. O'Connell, G. C. O'Sullivan, C. Brady, D. Roche, J. K. Collins, and F. Shanahan. 1998. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160:5669-5675.
8. Daniel, P. T., and P. H. Krammer. 1994. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J. Immunol. 152:5624-5632.
9. Disis, M. L., J. W. Smith, A. E. Murphy, W. Chen, and M. A. Cheever. 1994. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res. 54: 1071-1076.
10. Eischen, C. M., J. D. Schilling, D. H. Lynch, P. H. Krammer, and P. J. Leibson. 1996. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J. Immunol. 156:2693-2699.
11. Gimmi, C. D., B. W. Morrison, B. A. Mainprice, J. G. Gribben, V. A. Boussiotis, G. J. Freeman, S. Y. Lee Park, M. Watanabe, J. Gong, D. F. Hayes, D. W. Kufe, and L. M. Nadler. 1996. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated T cells. Nat. Med. 2:1367-1370.
12. Goedegebuure, P. S., C. C. Douville, J. M. Doherty, D. C. Linehan, K. Y. Lee, E. K. Ganguly, and T. J. Eberlein. 1997. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer. Cell. Immunol. 175:150-156.
13. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192.
14. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J.-C. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas (APO-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-1366.
15. Hunt, J. S., D. Vassmer, T. A. Ferguson, and L. Miller. 1997. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J. Immunol. 158:4122-4128.
16. Kang, S.-M., D. B. Schneider, Z. Lin, D. Hanahan, D. A. Dichek, P. G. Stock, and S. Baekkeskov. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:738-743.
17. Keane, M. M., S. A. Ettenberg, G. A. Lowrey, E. K. Russell, and S. Lipkowitz. 1996. Fas expression and function in normal and malignant breast cell lines. Cancer Res. 56:4791-4798.
18. Korbutt, G. S., J. F. Elliott, and R. V. Rajotte. 1997. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 46:317-322.
19. Lau, H. T., and C. J. Stoeckert. 1997. FasL - too much of a good thing? Nat. Med. 3:727-728.
20. Lau, H. T., M. Yu, A. Fontana, and C. J. Stoeckert, Jr. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 270:109-112.
21. Liles, W. C., P. A. Kiener, J. A. Ledbetter, A. Aruffo, and S. J. Klebanoff. 1996. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J. Exp. Med. 184:429-440.
22. Marrogi, A. J., A. Munshi, A. J. Merogi, Y. Ohadike, A. El-Habashi, O. L. Marrogi, and S. M. Freeman. 1997. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int. J. Cancer 74:492-501.
23. Mountz, J. D., T. Zhou, H. Bluethmann, J. Wu, and C. K. Edwards. 1994. Apoptosis defects analyzed in TcR transgenic and Fas transgenic lpr mice. Int. Rev. Immunol. 11:321-342.
24. Mulder, W. M. C., E. Bloemena, M. J. Stukart, J. A. Kummer, J. Wagstaff, and R. J. Scheper. 1997. T cell receptor-ζ and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 40:113-119.
25. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267:1449-1456.
26. Nagata, S., and T. Suda. 1995. Fas and Fas ligand: lpr and gld mutations. Immunol. Today 16:39-43.
27. Niehans, G. A., T. Brunner, S. P. Frizelle, J. C. Liston, C. T. Salerno, D. J. Knapp, D. R. Green, and R. A. Kratzke. 1997. Human lung carcinomas express Fas ligand. Cancer Res. 57:1007-1012.
28. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075-1082.
29. O'Connell, J., M. W. Bennett, G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1997. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol. Med. 3:294-300.
30. Ropponen, K. M., M. J. Eskelinen, P. K. Lipponen, E. Alhava, and V.-M. Kosma. 1997. Prognostic value of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. J. Pathol. 182:318-324.
31. Saas, P., P. R. Walker, M. Hahne, A.-L. Quiquerez, V. Schnuriger, G. Perrin, L. French, E. G. Van Meir, N. de Tribolet, J. Tschopp, and P.-Y. Dietrich. 1997. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99:1173-1178.
32. Schondorf, T., H. Engel, C. Lindemann, H. Kolhagen, A. A. von Rucker, and P. Mallmann. 1997. Cellular characteristics of peripheral blood lymphocytes and tumor-infiltrating lymphocytes in patients with gynaecological tumors. Cancer Immunol. Immunother. 44:88-96.
33. Seino, K., N. Kayagaki, K. Okumura, and H. Yagita. 1997. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:165-170.
34. Shiraki, K., N. Tsuji, T. Shioda, K. J. Isselbacher, and H. Takahashi. 1997. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA 94:6420-6425.
35. Strand, S., W. J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2:1361-1366.
36. Stuart, P. M., T. S. Griffith, N. Usui, J. Pepose, X. Yu, and T. A. Ferguson. 1997. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99:396-402.
37. Tanaka, M., T. Suda, T. Takahashi, and S. Nagata. 1995. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14:1129-1135.
38. Turley, J. M., T. Fu, F. W. Ruscetti, J. A. Mikovits, D. C. Bertolette III, and M. C. Birchenall-Roberts. 1997. Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. Cancer Res. 57:881-890.
39. Zhang, H., Y. Yang, J. L. Horton, E. B. Samoilova, T. A. Judge, L. A. Turka, J. M. Wilson, and Y. Chen. 1997. Amelioration of collagen-induced arthritis by CD95 (APO-1/Fas)-ligand gene transfer. J. Clin. Invest. 100:1951-1957.